This conference provides attendees with thoughtful insight from key industry leaders and academic researchers concerning cutting edge drug discovery science, preclinical development trends, analysis of key clinical-stage pain therapies and newly marketed products. We will highlight the most important developments in recent years in the field, including new research in genome-wide association studies, CGRP antagonists, NGF antagonists, sodium and calcium channel blockers, new research in biologic therapies, the genetic components of pain, abuse-resistant opioids, analysis of FDA’s REMS program and a plethora of other topics.